Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 1 2Phase 4 1

Status

Withdrawn 2Recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 2Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 4Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × posaconazole × Clear all
NCT07155226 2026-05-19

MOMENTUM

AstraZeneca

Phase 1/2 Recruiting
84 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04771130 2026-04-23

A Study of BGB-11417 in Participants With Myeloid Malignancies

BeOne Medicines

Phase 1/2 Recruiting
260 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Novartis

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03036046 2018-02-15

SAFEGUARDFP

F2G Biotech GmbH

Phase 1/2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡